**Insulin Lispro Injection**

**DEFINITION**
Insulin Lispro Injection is an isotonic, sterile solution of Insulin Lispro in Water for Injection. It has a potency of NLT 95.0% and NMT 105.0% of the potency stated on the label, expressed in USP Insulin Lispro Units/mL.

**IDENTIFICATION**
- **A.** The retention time of the major peak of the Sample solution corresponds to that of the Standard solution, as obtained in the Assay.

**ASSAY**
- **PROCEDURE**
  - **Solution A:** 28.4 g of anhydrous sodium sulfate in 1000 mL of water. Adjust with phosphoric acid to a pH of 2.3.
  - **System suitability solution:** 1 mg/mL of insulin lispro in 0.01 N hydrochloric acid. Allow to stand at room temperature to obtain a solution containing 0.8%–11% of A-21 desamido insulin lispro.
  - **Standard solution:** 0.7 mg/mL of USP Insulin Lispro RS in 0.01 N hydrochloric acid
  - **Sample solution:** Acidify each milliliter of Injection with 3 µL of 9.6 N hydrochloric acid. Quantitatively dilute a portion of the acidified solution with 0.01 N hydrochloric acid to obtain a solution containing 20 USP Insulin Lispro Units/mL.

**Chromatographic system**
(See Chromatography (621), System Suitability.)
- **Mode:** LC
- **Detector:** UV 214 nm
- **Column:** 4.6-mm × 10-cm; packing L1
- **Column temperature:** 40°
- **Flow rate:** 0.8 mL/min
- **Injection volume:** 20 µL

**System suitability**
Adjust the Mobile phase to obtain a retention time of about 24 min for the main insulin lispro peak.

**Sample:** System suitability solution (3 replicate injections)

**Suitability requirements**
- **Resolution:** NLT 3.0 between insulin lispro and A-21 desamido insulin lispro
- **Tailing factor:** NMT 1.5 for the insulin lispro peak
- **Relative standard deviation:** NMT 1.1% for the insulin lispro peak

**Analysis**
Samples: Standard solution and Sample solution
Calculate the potency, in USP Insulin Lispro Units/mL, of Injection taken:

\[
\text{Result} = \left( \frac{r_S}{r_I} \right) \times C_S \times D
\]

- \( r_S \) = peak response of insulin lispro from the Sample solution
- \( r_I \) = peak response of insulin lispro from the Standard solution
- \( C_S \) = concentration of USP Insulin Lispro RS in the Standard solution (USP Insulin Lispro Units/mL)
- \( D \) = dilution factor used to prepare the Sample solution

**Acceptance criteria:** 95.0%–105.0% of the potency stated on the label, expressed in USP Insulin Lispro Units/mL

**OTHER COMPONENTS**

**Change to read:**
- **Zinc Determination (591)**: 14–35 µg for every 100 USP Insulin Lispro Units

**PRODUCT-RELATED SUBSTANCES AND IMPURITIES**

**Change to read:**
- **Related Substances**
  - **Solvent:** 28.4 g of anhydrous sodium sulfate in 1000 mL of water. Adjust with phosphoric acid to a pH of 2.3.
  - **Solution A:** Acetonitrile and Solvent (18:82)
  - **Solution B:** Acetonitrile and Solvent (50:50)
  - **Mobile phase:** See Table 1.

<table>
<thead>
<tr>
<th>Time (min)</th>
<th>Solution A (%)</th>
<th>Solution B (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>81</td>
<td>19</td>
</tr>
<tr>
<td>60</td>
<td>61</td>
<td>19</td>
</tr>
<tr>
<td>83</td>
<td>51</td>
<td>49</td>
</tr>
<tr>
<td>84</td>
<td>81</td>
<td>19</td>
</tr>
<tr>
<td>94</td>
<td>81</td>
<td>19</td>
</tr>
</tbody>
</table>

**Chromatographic system**
(See Chromatography (621), System Suitability.)
- **Mode:** LC
- **Detector:** UV 214 nm
- **Column:** 4.6-mm × 25-cm; packing L1
- **Column temperature:** 40°
- **Flow rate:** 1 mL/min
- **Injection volume:** 20 µL

**System suitability**
Adjust the Mobile phase composition and the duration of the gradient elution phase to obtain a retention time of about 41 min for the main insulin lispro peak, with A-21 desamido insulin lispro eluting just prior to the start of the isocratic elution phase.

**Sample:** System suitability solution

**Suitability requirements**
- **Resolution:** NLT 2.5 between insulin lispro and A-21 desamido insulin lispro
- **Tailing factor:** NMT 2.0 for the insulin lispro peak

**Analysis**
Samples: Sample solution
Calculate the percentage of insulin lispro, A-21 desamido insulin lispro, and other impurities in the portion of Injection (ERR 1-Sep-2018) taken.

Calculate the percentage of insulin lispro (%):

\[
\text{Result} = \left( \frac{r_I}{r_S} \right) \times 100
\]

- \( r_S \) = peak response of insulin lispro from the Sample solution
- \( r_I \) = sum of the responses of all the peaks from the Sample solution

© 2018 The United States Pharmacopeial Convention All Rights Reserved.
Calculate the percentage of A-21 desamido insulin lispro (%D):

\[
\text{Result} = \left( \frac{r_D}{r_T} \right) \times 100
\]

- \( r_D \) = peak response of A-21 desamido insulin lispro from the Sample solution
- \( r_T \) = sum of the responses of all the peaks from the Sample solution

Calculate the percentage of other insulin lispro-related substances:

\[
\text{Result} = 100 - (\%I + \%D)
\]

Acceptance criteria:
- **Individual impurities**: NMT 1.50% of A-21 desamido insulin lispro
- **Total impurities**: NMT 4.00%, excluding A-21 desamido insulin lispro

**Physicochemical Analytical Procedures for Insulins** (121.1), *Limit of High Molecular Weight Proteins*

Proceed as directed in the chapter, except for the Sample solution. It meets the requirements.

**Sample solution**: Quantitatively add 4 µL of 6 N hydrochloric acid to each milliliter of an accurately measured volume of Injection, and mix.

Acceptance criteria: NMT 1.50%

**SPECIFIC TESTS**
- **pH** (791): 7.0–7.8
- **Particulate Matter in Injections** (788): Meets the requirements for small-volume injections
- **Bacterial Endotoxins Test** (85), Photometric Quantitative Techniques, Chromogenic Technique: NMT 80 USP Endotoxin Units per 100 USP Insulin Lispro Units, using the kinetic-chromogenic assay
- **Sterility Tests** (71), Test for Sterility of the Product to Be Examined, Membrane Filtration: Meets the requirements
- **Injections and Implanted Drug Products** (1): Meets the requirements

**ADDITIONAL REQUIREMENTS**
- **Packaging and Storage**: Preserve in tight, multiple-dose containers. Dispense in the unopened, multiple-dose container provided by the manufacturer. Store in a refrigerator, protect from sunlight, and avoid freezing.
- **Labeling**: Label it to indicate that it has been prepared with Insulin Lispro produced by methods based on recombinant DNA technology. Label it to state that it is to be stored in a refrigerator and that freezing is to be avoided. The label states the potency in USP Insulin Lispro Units/mL.
- **USP Reference Standards** (11) USP Insulin Lispro RS